Danaher Corp Stock (DHR) Moved Up by 3.32% on Oct 5: What Investors Need To Know
Danaher Corp (DHR) saw its stock rise by 3.32% on October 5, driven by favorable analyst revisions, a rebound in biopharmaceutical funding, and positive market sentiment following a structured CEO transition. The company, which reported annual revenue of $24.57B and net profit of $3.61B, outperformed its sector peers. Technical indicators suggest a neutral to buy condition, though risks like leadership transition friction and bioprocessing equipment order deferrals remain.
Abbott Laboratories Stock (ABT) Moved Up by 3.08% on Oct 5: Facts Behind the Movement
Abbott Laboratories (ABT) stock increased by 3.08% on October 5th, driven by FDA approval for enhanced features in its CardioMEMS heart failure system and the introduction of the CardioGuide HF App. Positive analyst sentiment, new product launches like SimpleScreen CRC, and reduced legal liabilities further boosted investor confidence. The company is set to release its third-quarter financial results later this month.
13,988 Medtronic PLC $MDT Shares Sold by Park National Corp OH
Park National Corp OH reduced its stake in Medtronic PLC by 12% in the third quarter, selling 13,988 shares. Despite this, institutional investors collectively own 82.06% of the company. Medtronic's stock recently rose 1.6% to $87.76, and analysts maintain a "Moderate Buy" rating with an average price target of $103.92, following strong quarterly earnings and a dividend announcement.
HeartBeam receives FDA breakthrough status for heart attack assessment
HeartBeam (NASDAQ: BEAT) has received FDA Breakthrough Device designation for its ECG system to assess potential heart attacks at home. This designation offers prioritized interaction with the FDA, though the company still needs to conduct a pivotal study and submit for separate clearance for this new indication. The system, which currently has clearance for arrhythmia assessment, will undergo a multicentre pivotal study to support its application for expanded indications.
Stryker Corp Stock (SYK) Moved Up by 3.32% on Oct 5: Facts Behind the Movement
Stryker Corp (SYK) saw its stock rise by 3.32% on October 5, driven by bargain hunting after a September sell-off and positive analyst commentary. Despite temporary supply chain and manufacturing disruptions in its Peripheral Vascular unit, the company's core business segments remain strong with solid organic sales growth. Investors are now focused on the upcoming third-quarter earnings for updates on supply chain resolution and margin progression.
Medtronic wins CPT approvals as TD Cowen maintains target for Medtronic stock
Medtronic has secured new Category I CPT approvals for its Altaviva and Symplicity Spyral systems, which become effective in January 2028 and are expected to support future reimbursement discussions. Despite these positive developments and strong Q1 fiscal 2027 revenue growth, Medtronic's stock currently trades below its prior close, though TD Cowen maintains a target of USD 110.00 for the company. The stock's market capitalization stands at USD 110.6 billion, with its NYSE 52-week range indicating it is trading above its yearly low.
Insulet (PODD) Reworks Debt Terms, Is It Still Trading At A Discount?
Insulet (PODD) recently reworked its credit agreement, converting $475 million of term loans into new debt with lower interest rates and expanding its revolving credit facility to $750 million. Despite a significant share price decline, the company's stock is still considered 23% undervalued, with a fair value of $171.91, according to an analysis based on its product roadmap and recurring revenue model. However, the narrative acknowledges risks related to type 2 user retention and potential recall-related quality issues.
Medtronic VenaSeal study shows 88.1% ulcer healing
Medtronic (NYSE: MDT) announced an 88.1% ulcer healing rate in a two-year study of its VenaSeal device for venous leg ulcers. The single-arm study of 125 patients also reported a 96% U.S. insurance coverage rate for the device. The results provide fresh clinical evidence for VenaSeal, with the market's reaction expected on the next trading day.
Intuitive Surgical Inc. Research & Ratings | ISRG
This article provides a detailed research and ratings overview for Intuitive Surgical Inc. (ISRG), including analyst ratings, price targets, stock grader information, company financials, and earnings estimates. It shows a consensus "Buy" rating with an average price target of $479.86 and details upcoming earnings reports.
Medtronic stock wins new CPT codes for two devices
Medtronic received new Category I CPT codes for its Altaviva and Symplicity Spyral devices, which will take effect in January 2028. This reimbursement milestone follows a strong fiscal Q1 2027 performance, where revenue exceeded expectations, leading management to raise its full-year guidance. Analysts maintain a "Moderate Buy" consensus for Medtronic stock, with an average price target above its current trading price.
CX Institutional Sells 86,818 Shares of Medtronic PLC $MDT
CX Institutional significantly reduced its stake in Medtronic PLC by 89% in the third quarter, selling 86,818 shares and retaining 10,707 shares valued at $924,000. Despite this, institutional investors collectively own 82.06% of Medtronic, with major firms like BlackRock and State Street increasing their positions. Medtronic reported strong quarterly financials, beating analyst expectations, and maintains a "Moderate Buy" consensus rating with an average price target of $103.92, alongside a declared quarterly dividend of $0.72 per share.
Intuitive Surgical Inc. Stock Grades | ISRG
This article provides detailed stock information for Intuitive Surgical Inc. (ISRG), including its current stock grade, analyst ratings, key financial metrics, and company overview. It highlights an average price target of $479.86 from 35 ratings and notes the company's P/E Ratio (TTM) of 44.92. The company specializes in robotic-assisted surgical solutions.
Medtronic : announces new prospective, global clinical evidence from the Spectrum Program for VenaSealTM closure system in advanced chronic venous disease
Medtronic announced new prospective findings from the VenaSeal™ Spectrum Program, reinforcing the efficacy of its VenaSeal™ closure system for advanced chronic venous disease. These findings were presented at the 2026 Venous Endovascular INterventional Strategies conference and follow expanded U.S. payer coverage for the system, increasing patient access. The VenaSeal system is a key product for Medtronic, a global leader in healthcare technology.
Medtronic's 49-Year Dividend Streak Faces a New Challenge: Is Growth Finally the Real Story?
Medtronic (MDT), known for its 49-year dividend streak, is experiencing a shift in its investment thesis due to remarkable growth in its cardiac ablation solutions, which grew 88% worldwide. While the dividend provides a floor for the stock, its rapid growth in medical device sectors like ablation is becoming the primary driver for investor interest. Despite its stock performance over the past five years, Medtronic is currently undervalued based on forward earnings, suggesting potential upside if this growth continues.
Medtronic (NYSE:MDT) Raised to Buy at Wall Street Zen
Wall Street Zen upgraded Medtronic (NYSE:MDT) to a "buy" rating, aligning with a "Moderate Buy" consensus from other analysts and an average price target of $103.92. The company recently surpassed quarterly earnings expectations, reporting adjusted EPS of $1.45 on revenues of $9.76 billion, a 13.7% year-over-year increase. Despite positive analyst sentiment and new product developments, the stock has experienced post-earnings pressure, with increased put-option activity suggesting investor concerns about future earnings momentum.
SSM Health touts seizure detection technology
SSM Health in Southern Illinois is now the first healthcare provider in the region to offer the Ceribell System, an FDA-cleared EEG technology for rapid detection of non-convulsive seizures. This system enhances neurological care for critically ill patients by providing faster diagnosis and treatment closer to home, available at SSM Health Good Samaritan Hospital in Mount Vernon and SSM Health St. Mary’s Hospital in Centralia. The technology helps clinicians quickly assess brain activity and continuously monitor patients, reducing the need for transfers and improving outcomes for challenging-to-detect non-convulsive seizures.
[Form 3] MiniMed Group, Inc. Initial Statement of Beneficial Ownership
This article reports on the filing of Form 3 by Sheila A. Denton for MiniMed Group, Inc. (MMED). The filing is an Initial Statement of Beneficial Ownership, indicating Denton's role as SVP, General Counsel & Corporate Secretary, and states that no securities are beneficially owned at the time of this initial report. The document was accepted by the SEC on October 1, 2026.
Edwards Lifesciences wins FDA approval for AUTUS
Edwards Lifesciences has received FDA approval for its AUTUS pediatric pulmonary valve, designed for children with congenital pulmonary valve disease. This innovative valve can be surgically implanted and later expanded via a catheter as the child grows, potentially reducing the need for multiple surgeries. The FDA's approval was based on a 62-child study, noting the valve's early performance but also flagging longer-term risks.
Is Medtronic (MDT) Reasonable On Cash Flow After Its $700 Million Robotics Bet?
Medtronic (MDT) shares have returned 25.2% over the past three years, prompting a review of whether its current share price aligns with its expected cash flows. Despite recent regulatory milestones and a $700 million robotics partnership, the stock's valuation, based on a Discounted Cash Flow (DCF) model, suggests it is meaningfully undervalued compared to its current price of $86.44. The DCF model indicates future cash flows support a higher intrinsic worth, with the upfront cost of the robotics partnership partially explaining the current price lag.
AMA approves permanent CPT codes for Medtronic's devices treating urinary incontinence and hypertension.
The American Medical Association (AMA) has approved new Category I CPT codes for Medtronic's Altaviva™ and Symplicity Spyral™ devices, which treat urge urinary incontinence and uncontrolled hypertension, respectively. These codes, effective January 2028, are expected to improve reimbursement and patient access to these minimally invasive therapies. Medtronic PLC shares saw a slight decline of 0.88% at the time of the report.
Medtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems
Medtronic plc announced that the American Medical Association (AMA) has approved new Category I Current Procedural Terminology (CPT®) codes for its Altaviva™ implantable tibial neuromodulation device and Symplicity Spyral™ renal denervation (RDN) system. These codes, effective January 2028, replace existing Category III codes and signify robust clinical evidence and physician adoption for solutions addressing urge urinary incontinence and hypertension. This development is expected to facilitate broader reimbursement pathways and patient access to these innovative technologies.
Medtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems
Medtronic plc announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for its Altaviva™ implantable tibial neuromodulation device and Symplicity Spyral™ renal denervation (RDN) system. These permanent codes, effective January 2028, reflect robust clinical evidence and physician adoption for these solutions addressing urge urinary incontinence and hypertension. The approvals are significant for the reimbursement pathway, aiming to reduce barriers to broader adoption and patient access.
Medtronic options flow dominated by large December put spread
Medtronic PLC (MDT) experienced significant options activity with a large December put spread dominating the flow. The trade involved 23,500 contracts of an $87.50/$82.50 put spread, accounting for about half of the day's total options volume. This activity suggests either a hedge against potential stock decline or a bearish bet targeting the low $80s for MDT, as put volume significantly outpaced call volume.
Danaher Corp Stock (DHR) Moved Down by 3.29% on Oct 1: What Investors Need To Know
Danaher Corp (DHR) stock declined by 3.29% on October 1st due to profit-taking in high-valuation life sciences and healthcare stocks, as well as investor caution ahead of its third-quarter earnings release. Despite strong fundamentals and technical buy signals from MACD, short-term price action will remain sensitive to macroeconomic sentiment and order visibility. The article also highlights company-specific risks including executive leadership transition, bioprocessing revenue deferrals, elevated valuation, and M&A balance sheet leverage with China headwinds.
Medtronic stock after-hours at EUR 76.62: plus 0.05 percent versus prior close
Medtronic's stock saw a slight increase of 0.05 percent in after-hours trading, reaching EUR 76.62 at 6:43 p.m. CEST on October 1, 2026. This comes as the company's MiniMed exchange offer is set to expire on October 9, allowing shareholders to exchange Medtronic ordinary shares for MiniMed common stock. The indicative exchange ratio is 4.5939 MiniMed shares per Medtronic ordinary share.
Confluence Investment Management LLC Cuts Position in Medtronic PLC $MDT
Confluence Investment Management LLC reduced its stake in Medtronic PLC by 10.9% in the third quarter, selling 21,230 shares but retaining 174,010 shares valued at approximately $15.0 million. Medtronic reported strong quarterly earnings of $1.45 per share and revenue of $9.76 billion, both exceeding analyst expectations, with revenue up 13.7% year over year. The company declared a quarterly dividend of $0.72 per share, yielding 3.3% annually, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $103.92.
Medtronic drug-coated balloon gets FDA breakthrough status
Medtronic has received FDA breakthrough device designation for its drug-coated balloon catheter designed to treat peripheral artery disease (PAD) below the knee. This is a significant development as current drug-coated balloons are not indicated for use in this area, which is historically difficult to treat and can lead to amputation. Medtronic plans a randomized pivotal trial with approximately 400 patients to study the effectiveness of its IN.PACT BTK paclitaxel-coated device.
Medtronic reveals cardiac mapping and ablation software clearances
Medtronic announced it has received regulatory clearances for new cardiac mapping and ablation software in both the U.S. and Europe. The clearances are for its Affera Prism-2 Mapping Software and a CE mark for the PulseSelect ProxBox Adapter with Proximity Indicator software, aiming to enhance the company's position in the competitive pulsed field ablation market. These software advancements are designed to provide physicians with better visualization and real-time feedback during cardiac ablation procedures.
Gilead Sciences, Inc. (GILD) stock price, news, quote and history
This article provides a comprehensive overview of Gilead Sciences, Inc. (GILD) stock, including its current price, recent news headlines, and performance data. It highlights the stock's trading activity, various news articles discussing its trends and comparisons with other healthcare stocks, and its trailing total returns against the S&P 500. The data indicates strong performance for GILD across different timeframes.
Across 13 countries, Orchestra BioMed (OBIO) exceeds its blood-pressure trial enrollment target.
Orchestra BioMed Holdings, Inc. (OBIO) announced that its BACKBEAT global pivotal trial has exceeded its enrollment target, with 330 patients randomized across 81 sites in 13 countries as of September 30, 2026. The trial evaluates AVIM Therapy for uncontrolled hypertension in pacemaker-indicated patients. Positive primary endpoint results, expected in Q2 2027, will support Medtronic's marketing applications to regulatory agencies.
History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.
Johnson & Johnson (JNJ) significantly outperformed Medtronic (MDT) over the last decade due to its strategy of spinning off businesses and reinvesting capital. However, the author suggests Medtronic could be a better investment for the next decade, as it is now adopting a similar strategy with its diabetes business, potentially unlocking shareholder value and leading to higher returns from its lower valuation and higher dividend yield.
Medtronic raises fiscal 2027 outlook for Medtronic stock
Medtronic (ISIN IE00BTN1Y115) has raised its fiscal 2027 organic revenue growth guidance to 7.25-7.75% after a strong first quarter performance, with revenue of USD 9.756 billion. The company also adjusted its fiscal 2027 diluted non-GAAP earnings per share guidance to USD 5.94-USD 6.00. Analysts have largely maintained Buy ratings with target prices ranging from USD 103.92 to USD 110.00, and Medtronic's next key events include an earnings report in November and an Investor Day in December.
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
Orchestra BioMed has announced that it has exceeded its enrollment target for the BACKBEAT Global Pivotal Trial of its AVIM Therapy, with 330 patients randomized across 81 sites in 13 countries. This trial evaluates AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension, aiming to demonstrate its efficacy in lowering blood pressure. The company expects to submit primary endpoint data for presentation in Q2 2027, with Medtronic planning future marketing application submissions based on these results.
GE HealthCare hires new global chief AI officer
GE HealthCare has appointed Rodolphe Katra, former global chief AI officer at Medtronic, as its new global chief AI officer. Katra will report to CTO Taha Kass-Hout and focus on integrating devices, software, and data to enhance AI strategies. This appointment follows the departure of GE HealthCare's first chief AI officer, Parminder Bhatia, and aims to further cement the company's leadership in AI-enabled medical devices, of which it currently has 134 FDA-authorized.
Medtronic stock trades at EUR 76.28 as guidance rises
Medtronic stock is trading at EUR 76.28, reflecting a slight dip despite the company's strong Q1 FY27 financial results. The medical device giant reported a 13.7% year-over-year revenue increase to USD 9.756 billion and raised its full-year organic revenue growth guidance to 7.25%-7.75%. Analysts maintain a positive outlook, with a consensus price target around USD 103.92, indicating potential upside from its current market price.
Medtronic gains regulatory clearances for cardiac software
Medtronic (NYSE: MDT) has received regulatory clearances from the U.S. FDA and CE Mark for its Affera Prism-2 Mapping Software and a CE Mark for its PulseSelect ProxBox Adapter with Proximity Indicator software. These advancements aim to improve cardiac ablation procedures for arrhythmias by providing detailed 3D heart maps and real-time feedback for catheter placement, reducing reliance on X-ray imaging. The company's innovative technologies, including the Sphere-9 Catheter and PulseSelect PFA System, are designed to enhance the safety and effectiveness of cardiac treatments.
Medtronic announces regulatory milestones for newest cardiac mapping and ablation software
Medtronic has announced key regulatory milestones for its cardiac mapping and ablation software, including FDA clearance and CE Mark for the latest Affera™ Prism-2 Mapping Software and CE Mark for the PulseSelect ProxBox™ Adapter with Proximity Indicator software. These advancements enhance the company's cardiac ablation portfolio by expanding integrated mapping capabilities and providing real-time tissue proximity feedback, aiming to improve precision and patient care for heart rhythm disorders. The new software tools are designed to support efficient mapping, informed decision-making, and reduce reliance on fluoroscopy during procedures.
Medtronic's (MDT) Buy Rating Reaffirmed at TD Cowen
TD Cowen has reaffirmed its "buy" rating for Medtronic (NYSE:MDT) and set a $110.00 price target, indicating a potential upside of 26.20%. Other analysts have also issued "buy" or "outperform" ratings, contributing to a consensus "Moderate Buy" with an average price target of $103.92. The company recently reported strong earnings, exceeding analyst estimates, and has seen various institutional investors adjust their stakes.
Medtronic Named to Fortune 2026 ‘Change the World’ List for Touch Surgery™ Ecosystem and Healthy Neighbor
Medtronic has been recognized on the Fortune 2026 'Change the World' list for its Touch Surgery™ ecosystem and Healthy Neighbor program through Medtronic LABS. The Touch Surgery™ ecosystem utilizes AI and livestreaming to enhance surgical training and collaboration, while the Healthy Neighbor program, in partnership with Virtua Health, addresses chronic health disparities in underserved communities like Camden, New Jersey, by providing community health workers and digital health platforms, showing significant improvements in blood pressure and A1C levels. This recognition highlights Medtronic's commitment to improving healthcare outcomes globally.
Abbott launches SimpleScreen CRC, a blood-based colorectal cancer screening test for adults 45+, covered by Medicare.
Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in adults aged 45 and older. This test is covered by Medicare and aims to increase screening rates by offering a convenient alternative to traditional methods. Despite this new product, Abbott Laboratories (ABT) stock is trading near its 52-week low, with more selling pressure observed on the Pluang platform.
Medtronic Named to Fortune 2026 'Change the World' List for Touch Surgery(TM) Ecosystem and Healthy Neighbor
Medtronic has been recognized on the FORTUNE 2026 'Change the World' list for its Touch Surgery™ ecosystem and Healthy Neighbor program through Medtronic LABS. The Touch Surgery™ ecosystem utilizes AI to enhance surgical training and collaboration, while the Healthy Neighbor program, in partnership with Virtua Health, addresses health disparities in Camden, New Jersey, focusing on chronic conditions like diabetes and hypertension. This recognition highlights Medtronic's commitment to improving healthcare outcomes globally through technological innovation and community-based solutions.
A successor's appointment could set the CEO's retirement date at AngioDynamics (ANGO). There's another trigger.
AngioDynamics CEO James C. Clemmer announced his intention to retire by November 30, 2026, or upon the appointment of a successor, with the possibility of monthly extensions by mutual agreement. The company recently amended its fiscal 2026 annual report to include updated XBRL tagging and disclosed performance against cash-incentive targets, showing net sales of $320.2 million against a $312 million target and adjusted EBITDA of $18.2 million versus a $10.5 million target. Executive compensation for fiscal 2026 was largely performance-based, with cash incentive payouts at 180% of target for named executive officers.
Nexalin Technology Taps Neuromodulation Commercial
Nexalin Technology, developer of Deep Intracranial Frequency Stimulation (DIFS™) technology, has appointed Robert DiTota as Senior Strategic Advisor, Global Commercialization. This move signifies the company's shift from clinical development to commercializing its Gen-2 SYNC device, already approved in China, Brazil, Oman, and Israel, with plans to expand into the US and Europe. DiTota, with over two decades of experience in neuromodulation at Abbott and Medtronic, will advise on global commercial strategy and infrastructure development.
A brain-stimulation device is approved in four countries. Nexalin is building a sales network.
Nexalin Technology (NXL) has appointed Robert DiTota as Senior Strategic Advisor for global commercialization, effective September 15, 2026, to leverage existing device approvals into sales. DiTota, with extensive experience from Medtronic and Abbott, will focus on distribution, market development, and infrastructure for Nexalin's Gen-2 SYNC device, which is already approved in China, Brazil, Oman, and Israel. The company plans to expand into the U.S. and Europe as regulatory milestones are met, building on positive clinical trial results for its device.
Medtronic (NYSE:MDT) Stock Price
This page provides an overview of Medtronic (NYSE:MDT) stock, including its current price performance, analyst consensus targets, and various user-submitted fair value narratives. It highlights recent news and updates, key financial details, and information about the company's segments and competitors. The stock is currently trading at US$89.50, with a fair value estimate of US$98.00, suggesting it is undervalued.
Medtronic stock after-hours at EUR 76.43: minus 2.16 percent versus prior close
Medtronic stock closed after-hours at EUR 76.43, a decrease of 2.16 percent from its prior close of EUR 78.12. This follows Medtronic's announcement of a roughly $700 million robotics partnership with Cornerstone Robotics to distribute the Sentire surgical system in selected markets outside the United States. The partnership aims to expand access to robotic-assisted surgery and provide more options for surgeons and health systems.
Carlsmed names new CFO
Carlsmed has appointed Richard Heppenstall, formerly CFO of ZimVie, as its new Chief Financial Officer, replacing Leo Greenstein. Despite Greenstein's departure, analysts expect no significant change in Carlsmed's strategy. The company reaffirmed its full-year sales guidance of $74 million to $78 million, anticipating 50% growth over 2025 sales, driven by surgeon onboarding and new product launches like the Aprevo platform.
3 Historically Stable Dividend Raisers in Medical Devices Offering Solid Yields With Fortress-Like Growth
This article highlights three medical device companies—Abbott Laboratories (ABT), Medtronic (MDT), and Becton Dickinson (BDX)—as stable dividend raisers offering solid yields for retirement portfolios. These companies benefit from consistent demand for their products, allowing them to increase dividends annually. The article details each company's dividend history, safety, and investment case, noting their strong free cash flow and modest forward earnings multiples.
GE HealthCare Technologies Inc. (GEHC) Latest Stock News & Headlines
This article provides a compilation of recent news and headlines concerning GE HealthCare Technologies Inc. (GEHC). It covers various topics including dividend announcements, stock performance analysis, market trends in remote cardiac monitoring, and the appointment of new board members. The collected headlines also discuss GEHC's strategic moves like the launch of its CareIntellect AI tool and potential acquisitions.
Minimed Group Inc (MMED-Q) Stock Price and News
This article provides stock information and recent news for Minimed Group Inc. (MMED-Q), a diabetes management company. It includes real-time stock data, analyst ratings, and a list of news articles detailing financial performance, analyst recommendations, and investor conference participation. The company offers insulin delivery devices, continuous glucose monitors, and related software and services.
